Retinal images and CIMT
Paired retinal photographs and CIMT measurements allow us to investigate vascular associations.
Research for
clinical decisions.
We investigate whether retinal image analysis can provide useful information for cardiovascular risk assessment in hospital care.
Not Prediscan™ patient data.
Why the retina?
Why retinal images?
Retinal photographs offer a non-invasive view of blood vessels. Published deep-learning research has examined their association with cardiovascular risk factors.
These findings inform our research. They do not establish the clinical performance of AtheroSEE AI™.
Read the foundational researchThe research
Our cardiovascular research.
We study retinal images alongside carotid intima-media thickness (CIMT), an ultrasound measurement of the carotid artery wall.
Discuss research collaborationClinical evaluation
Multi-centre clinical validation in India is planned. Internal testing alone does not establish performance in clinical care.
Intended use
The intended use is cardiovascular risk triage. The clinician remains responsible for diagnosis and further assessment.
Clinical research collaborators
Institutions collaborating with Prediscan™ on clinical research.
Medical Sciences
for Women
& Hospital
What needs to be established
What clinical evaluation must establish.
CIMT provides a clinical measurement for this research. It is not equivalent to a diagnosis or a prediction of a future cardiovascular event.
Clinical evaluation must account for image quality, patient characteristics and differences between hospitals. These factors determine how useful a model may be beyond internal testing.
Research in progress
Beyond cardiovascular risk.
We are also exploring retinal imaging in bone, maternal and liver health.
Osteoporosis
Studying whether retinal features are associated with osteoporosis and could inform further bone-health assessment.
Pre-eclampsia
Exploring retinal information that may be relevant to pre-eclampsia risk during pregnancy.
Liver disease
Examining possible associations between retinal features and liver disease.
These exploratory areas are not validated detection capabilities or available clinical indications. Each requires separate clinical evaluation.
Development & availability.
AtheroSEE AI™ is in development and is available for demonstration and research discussions. Routine clinical use requires clinical validation and applicable regulatory authorisation.